Howmet Aerospace Inc. (HWM)
NYSE: HWM · Real-Time Price · USD
180.75
-0.59 (-0.33%)
At close: Aug 8, 2025, 4:00 PM
181.46
+0.71 (0.39%)
After-hours: Aug 8, 2025, 7:42 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
The 13 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $173.08, which forecasts a -4.24% decrease in the stock price over the next year. The lowest target is $125 and the highest is $215.
Price Target: $173.08 (-4.24%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 6 | 6 | 5 |
| Buy | 7 | 6 | 6 | 6 | 6 | 6 |
| Hold | 2 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Total | 17 | 17 | 17 | 16 | 15 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $185 → $215 | Strong Buy | Maintains | $185 → $215 | +18.95% | Aug 5, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $150 → $190 | Buy | Maintains | $150 → $190 | +5.12% | Aug 4, 2025 |
| Barclays | Barclays | Buy Maintains $140 → $190 | Buy | Maintains | $140 → $190 | +5.12% | Aug 4, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $170 → $210 | Buy | Maintains | $170 → $210 | +16.18% | Jul 17, 2025 |
| Susquehanna | Susquehanna | Buy Maintains $170 → $210 | Buy | Maintains | $170 → $210 | +16.18% | Jul 14, 2025 |
Financial Forecast
Revenue This Year
8.16B
from 7.43B
Increased by 9.88%
Revenue Next Year
9.00B
from 8.16B
Increased by 10.22%
EPS This Year
3.55
from 2.81
Increased by 26.23%
EPS Next Year
4.19
from 3.55
Increased by 18.02%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 8.7B | 10.0B | 11.1B | |
| Avg | 8.2B | 9.0B | 9.8B | |
| Low | 7.8B | 8.2B | 8.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 17.1% | 22.9% | 23.0% | |
| Avg | 9.9% | 10.2% | 9.2% | |
| Low | 5.2% | 0.3% | -4.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 3.82 | 5.16 | 6.18 | |
| Avg | 3.55 | 4.19 | 4.89 | |
| Low | 3.33 | 3.58 | 4.17 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 36.0% | 45.4% | 47.7% | |
| Avg | 26.2% | 18.0% | 16.8% | |
| Low | 18.6% | 0.8% | -0.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.